Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
Bionano Genomics, Inc. reported interim unaudited results showing recurring losses and cash constraints. As of June 30, 2025 the company held $3.6 million in cash and cash equivalents, $12.9 million in short-term investments, $11.0 million in restricted short-term investments and working capital of $18.5 million. The company had $12.1 million principal outstanding under its senior secured convertible debentures and an accumulated deficit of $703.2 million. The company used $6.3 million of cash in operations during the six months ended June 30, 2025 and management stated there is substantial doubt about its ability to continue as a going concern without raising additional capital. Management expects operating losses and negative cash flows to continue for at least the next year and believes existing resources are sufficient into at least the first quarter of 2026 assuming current plans. Significant financing and conversion activity included a reverse stock split (1-for-60), registered direct offerings in January 2025 (~$10.0 million gross proceeds) and at-the-market sales under an ATM Agreement with H.C. Wainwright in 2025 (multiple tranches totaling millions in gross proceeds). Restructuring actions in 2023 and 2024 reduced headcount and caused related charges and impairments previously recorded.
Bionano Genomics, Inc. filed a Form 8-K reporting that on August 14, 2025 it issued a press release containing its financial results for the quarter ended June 30, 2025. The filing states the full press release is attached as Exhibit 99.1 to the report and notes that, consistent with applicable SEC guidance, the press release and related information are furnished rather than "filed" and are therefore not subject to Section 18 liabilities or automatically incorporated by reference into other SEC filings. The 8-K also contains a standard forward-looking statements caution describing assumptions, risks (including financing needs and geopolitical and macroeconomic uncertainty) and the possibility that actual results may differ materially from expectations.
Bionano Genomics (NASDAQ: BNGO) has filed an 8-K/A to amend its previous filing from June 13, 2025, correcting voting results for two key proposals. The amendment specifically addresses errors in reporting Broker Non-Votes and Votes For on Proposals 3 and 4.
Key Corrections:
- Proposal 3 (Ratification of BDO USA as auditor): Corrected to show 0 Broker Non-Votes instead of previously reported 769,744
- Proposal 4 (Warrant Exercise Share Issuance): Updated to show 396,176 Votes For (previously 369,176) and 769,744 Broker Non-Votes (previously unreported)
The corrections do not affect the outcome of either vote. Proposal 4 approved the issuance of up to 661,374 shares of common stock related to warrant exercises from a January 3, 2025 securities purchase agreement with institutional investors, in compliance with Nasdaq Listing Rule 5635(d).